KR102162129B9 - 항-갈렉틴-9 항체 및 이의 용도 - Google Patents

항-갈렉틴-9 항체 및 이의 용도

Info

Publication number
KR102162129B9
KR102162129B9 KR1020207014697A KR20207014697A KR102162129B9 KR 102162129 B9 KR102162129 B9 KR 102162129B9 KR 1020207014697 A KR1020207014697 A KR 1020207014697A KR 20207014697 A KR20207014697 A KR 20207014697A KR 102162129 B9 KR102162129 B9 KR 102162129B9
Authority
KR
South Korea
Prior art keywords
galectin
antibodies
Prior art date
Application number
KR1020207014697A
Other languages
English (en)
Other versions
KR20200064150A (ko
KR102162129B1 (ko
Inventor
쇼헤이 코이데
조지 밀러
아키코 코이데
린샤오 첸
알렉산드라 필리포빅
에릭 엘렌코
요셉 볼렌
Original Assignee
뉴욕 유니버시티
퓨어테크 헬스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66246040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102162129(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴욕 유니버시티, 퓨어테크 헬스, 엘엘씨 filed Critical 뉴욕 유니버시티
Publication of KR20200064150A publication Critical patent/KR20200064150A/ko
Application granted granted Critical
Publication of KR102162129B1 publication Critical patent/KR102162129B1/ko
Publication of KR102162129B9 publication Critical patent/KR102162129B9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
KR1020207014697A 2017-10-27 2018-10-29 항-갈렉틴-9 항체 및 이의 용도 KR102162129B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762578111P 2017-10-27 2017-10-27
US62/578,111 2017-10-27
US201862665175P 2018-05-01 2018-05-01
US62/665,175 2018-05-01
US201862736317P 2018-09-25 2018-09-25
US62/736,317 2018-09-25
PCT/US2018/058028 WO2019084553A1 (en) 2017-10-27 2018-10-29 ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

Publications (3)

Publication Number Publication Date
KR20200064150A KR20200064150A (ko) 2020-06-05
KR102162129B1 KR102162129B1 (ko) 2020-10-06
KR102162129B9 true KR102162129B9 (ko) 2023-02-08

Family

ID=66246040

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014697A KR102162129B1 (ko) 2017-10-27 2018-10-29 항-갈렉틴-9 항체 및 이의 용도

Country Status (11)

Country Link
US (5) US10344091B2 (ko)
EP (1) EP3625263A4 (ko)
JP (4) JP6873445B2 (ko)
KR (1) KR102162129B1 (ko)
CN (2) CN111511765B (ko)
AU (3) AU2018355588C1 (ko)
CA (1) CA3080120C (ko)
IL (2) IL274152B (ko)
SG (1) SG11202003652QA (ko)
WO (1) WO2019084553A1 (ko)
ZA (1) ZA202102905B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6873445B2 (ja) 2017-10-27 2021-05-19 ニューヨーク ユニバーシティ 抗ガレクチン−９抗体及びその使用
CN111256416A (zh) * 2018-11-30 2020-06-09 青岛海尔股份有限公司 风冷冰箱
US20220204629A1 (en) * 2019-03-25 2022-06-30 New York University Anti-galectin-9 antibodies and uses thereof
JP2022531408A (ja) * 2019-05-01 2022-07-06 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用
KR20220016152A (ko) * 2019-05-31 2022-02-08 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 항-gal9 결합분자 활성화
EP3976102A4 (en) * 2019-05-31 2023-07-12 The Council of the Queensland Institute of Medical Research IMMUNE-INHIBITION ANTI-GAL9 BINDING MOLECULES
US20220242955A1 (en) * 2019-07-11 2022-08-04 Dana-Farber Cancer Institute, Inc. Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
AU2020329092A1 (en) * 2019-08-14 2022-03-31 Modmab Therapeutics Inc. Antibodies that bind to LRP5 proteins and methods of use
AU2021205143A1 (en) * 2020-01-07 2022-07-28 Hifibio, Inc. Anti-Galectin-9 antibody and uses thereof
WO2022020745A1 (en) * 2020-07-23 2022-01-27 Emory University Galectin-9 specific binding agents for use in treating cancer
AU2021322183A1 (en) * 2020-08-04 2023-03-02 Exelixis, Inc. PD-L1 binding agents and uses thereof
AU2021320658A1 (en) * 2020-08-04 2023-03-02 Exelixis, Inc. CD47 binding agents and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途
CN116782934A (zh) * 2020-10-26 2023-09-19 纯技术Lyt股份有限公司 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
WO2022109302A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
AU2022227029A1 (en) * 2021-02-26 2023-08-31 New York University Compositions and methods comprising antibodies that bind to covalent peptide conjugates
IL308020A (en) * 2021-04-30 2023-12-01 Puretech Lyt Inc Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatment
WO2023060192A2 (en) * 2021-10-06 2023-04-13 The University Of Chicago Survivin targeting polypeptides for detection and treatment of cancer
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2024006933A1 (en) * 2022-06-29 2024-01-04 Puretech Lyt, Inc. Treatment of hematological malignancies with antibodies inhibiting galectin-9

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427523A1 (en) 2000-11-01 2003-04-30 Galpharma Co., Ltd. Predicting agent for metastasis
JP2004244411A (ja) * 2003-01-24 2004-09-02 Galpharma Co Ltd ガレクチン９含有医薬
EP1586325A1 (en) * 2003-01-24 2005-10-19 Galpharma Co., Ltd. Drugs containing galectin 9
US9050352B2 (en) 2003-10-16 2015-06-09 Stephen John Ralph Immunomodulating compositions and uses therefor
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2414804T3 (es) 2008-01-18 2013-07-22 Genentech, Inc. Métodos y composiciones que se dirigen a la poliubiquitina
ES2337224B1 (es) 2008-06-11 2011-02-17 Consejo Superior De Investigaciones Cientificas (Csic) (40%) Anticuerpo anti-dectin-1 humano, hibridoma productor de dicho anticuerpo y sus aplicaciones.
US20110151490A1 (en) 2008-07-18 2011-06-23 Oragenics, Inc. Compositions for the Detection and Treatment of Colorectal Cancer
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
JP6163429B2 (ja) 2010-11-10 2017-07-12 ジェネンテック， インコーポレイテッド 神経疾患免疫治療のための方法及び組成物
CA2820642A1 (en) 2010-12-09 2012-06-14 Galpharma Co., Ltd. Galectin-9-secreting cell, and production method and use of the same
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US20140378531A1 (en) 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CN106999548A (zh) 2014-07-14 2017-08-01 昆士兰医学研究所理事会 半乳糖凝集素免疫疗法
SG11201701340RA (en) 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
US10640549B2 (en) * 2014-10-17 2020-05-05 University Of Virginia Patent Foundation Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein
AU2015343425A1 (en) 2014-11-04 2017-05-25 Dana-Farber Cancer Institute, Inc. Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US20160209425A1 (en) 2015-01-16 2016-07-21 New York University Use of dectin-1 activators for treatment of liver disorders
US10294294B2 (en) 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
US20190292259A1 (en) 2016-05-24 2019-09-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
EP3490568A4 (en) 2016-07-29 2020-04-15 New York University TREATMENT OF A SOLID TUMOR BY TARGETING DECTIN 1 SIGNALING
WO2018053597A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
JP6873445B2 (ja) 2017-10-27 2021-05-19 ニューヨーク ユニバーシティ 抗ガレクチン−９抗体及びその使用
WO2020014465A1 (en) 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US20220204629A1 (en) 2019-03-25 2022-06-30 New York University Anti-galectin-9 antibodies and uses thereof
JP2022531408A (ja) 2019-05-01 2022-07-06 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用

Also Published As

Publication number Publication date
US11414492B2 (en) 2022-08-16
KR20200064150A (ko) 2020-06-05
CA3080120C (en) 2023-11-21
IL274152A (en) 2020-06-30
AU2018355588C1 (en) 2023-04-27
ZA202102905B (en) 2023-04-26
KR102162129B1 (ko) 2020-10-06
US20190127472A1 (en) 2019-05-02
JP6873445B2 (ja) 2021-05-19
AU2020294364A1 (en) 2021-02-18
US10344091B2 (en) 2019-07-09
JP2021153585A (ja) 2021-10-07
SG11202003652QA (en) 2020-05-28
EP3625263A1 (en) 2020-03-25
CN111511765B (zh) 2022-05-27
NZ764590A (en) 2020-12-18
JP7092317B2 (ja) 2022-06-28
US20200010551A1 (en) 2020-01-09
AU2023285898A1 (en) 2024-01-18
JP7307443B2 (ja) 2023-07-12
US20190256604A1 (en) 2019-08-22
US10450374B2 (en) 2019-10-22
CN115261392A (zh) 2022-11-01
US20220332830A1 (en) 2022-10-20
JP2023116789A (ja) 2023-08-22
IL274152B (en) 2021-02-28
AU2018355588B2 (en) 2020-10-15
JP2022116325A (ja) 2022-08-09
AU2018355588A1 (en) 2020-06-11
WO2019084553A1 (en) 2019-05-02
JP2021501120A (ja) 2021-01-14
IL280648A (en) 2021-03-25
AU2020294364B2 (en) 2023-09-21
EP3625263A4 (en) 2021-05-05
CA3080120A1 (en) 2019-05-02
US20220340666A1 (en) 2022-10-27
CN111511765A (zh) 2020-08-07
US11629191B2 (en) 2023-04-18

Similar Documents

Publication Publication Date Title
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
IL271477A (en) Anti-cd166 antibodies and their uses
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
IL269134A (en) Antibodies against PAR2 and their use
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3359563T3 (da) Antigenreceptorer og anvendelser deraf
IL272476A (en) Anti-Apelin antibodies and their uses
IL273157A (en) Antibodies specific to AXL and their uses
DK3448419T3 (da) Interferon-beta-antistoffer og anvendelser deraf
IL271398A (en) Anti-l1-cam antibodies and uses thereof
MA49905A (fr) Polyesteramines et polyesterquats
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
GB201712032D0 (en) Antibodies and uses thereof
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
DK3484921T3 (da) Anti-IL-22R antistoffer

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J202 Request for trial for correction [limitation]
J301 Trial decision

Free format text: TRIAL NUMBER: 2022105000080; TRIAL DECISION FOR CORRECTION REQUESTED 20220916

Effective date: 20230126